Tesaro Shares Multitude of Ovarian Cancer Treatment Findings at Madrid Conference

Tesaro Shares Multitude of Ovarian Cancer Treatment Findings at Madrid Conference
Half of ovarian cancer patients in a small study responded to a combination of Tesaro’s Zejula and Genentech’s Avastin, according to a presentation Tesaro made at the European Society of Medical Oncology (ESMO) 2017 Meeting in Madrid. It was one of a host of presentations the company delivered on Zejula (niraparib) and another of its ovarian cancer therapies, TSR-042. The

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

2 comments

  1. Nancy B says:

    Are these options available at all cancer facilities?? I treat at MD ANDERSON in Camden, NJ. I’m still in treatment for Fallopian tube serous carcinoma; Stage IIIC. Just wondering what my treatments options are moving forward. I’m currently on Gemzar!!! I’ve been on a number of drugs and I’m just wondering with all this talk about Car-T therapy where it’s being offered.

    • Magdalena Kegel says:

      Dear Nancy,
      We at Ovarian Cancer News have no good insight into which treatments that are offered at different centers. We are not physicians, and can’t advise you on treatment matters, so I suggest that you discuss this with your physician. If you wish to participate in a clinical trial of CAR T-cells (which is not an approved treatment in faloppian tube or ovarian cancer) you could also ask your physician to help you find a suitable trial.

Leave a Comment

Your email address will not be published. Required fields are marked *